))
Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
R
ReachMD CME
CME credits: 0.25 Valid until: 15-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/dont-let-hyperkalemia-get-you-down-when-potassium-goes-up-in-your-patients-with-heart-failure/13258/ In heart failure, there is a propensity to down-titrate or discontinue guideline-directed medical therapy in the presence of hyperkalemia, even thoug…
CME credits: 0.50 Valid until: 15-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/altering-the-course-of-type-1-diabetes-prevention-trials/14287/ Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challen…
CME credits: 0.25 Valid until: 07-03-2024 Claim your CME credit at https://reachmd.com/programs/cme/cervical-cancer-screening-the-case-of-the-young-patient/14673/ Explore the case of a young patient to see the ACS and ASCCP cervical cancer screening guidelines in action. Who needs to be screened, how is it best to screen, and what's the best test? …
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-the-treatment-of-recurrentmetastatic-hnscc-a-multifactorial-path/14953/ KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remai…
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/molecular-driven-treatment-advances-in-her2-metastatic-colorectal-cancer/14949/ Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer? Listen in as Drs. Tanios Bekii-Saab and Jolee…
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/parallels-between-kidney-transplantation-and-maternal-anti-fetal-rejection/13911/ Program Chairman: Roberto Romero, MD, DMedSci Chief, Perinatology Research Branch Division of Maternal-Fetal Medicine and Obstetrics Division of Intramural Research NIC…
CME credits: 1.00 Valid until: 24-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/btki-breakthroughs-overcoming-treatment-resistance-in-cll-mcl/14825/ Bruton’s tyrosine kinase inhibitors (BTKi) have transformed treatment for people with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell malignancies. …
R
ReachMD CME
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-patient-with-low-risk-of-genitourinary-bleed-for-established-vte-with-cancer/14724/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the fac…
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-a-patient-with-cancer-and-with-catheter-related-thrombosis/14726/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple opti…
R
ReachMD CME
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/prophylaxis-of-medically-treated-patient-with-cancer-and-reduced-mobility-in-hospital/14722/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of…
R
ReachMD CME
1
Treatment of Patient With Low Risk of Gastrointestinal Absorption Impairment for Established VTE With Cancer
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-patient-with-low-risk-of-gastrointestinal-absorption-impairment-for-established-vte-with-cancer/14725/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique cha…
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-make-sense-of-guidelines-and-apply-to-our-everyday-practice/14728/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple option…
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/treatment-of-patients-with-established-vte-with-cancer-and-covid-19/14723/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the face of multiple options …
R
ReachMD CME
1
Primary Thromboprophylaxis of Patient at High-Risk of VTE Who Is Receiving Systemic Anticancer Therapy
CME credits: 1.00 Valid until: 17-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/primary-thromboprophylaxis-patient-high-risk-vte-who-receiving-systemic-anticancer-therapy/14727/ There is not a “one size fits all approach” for managing cancer-associated venous thrombosis (CAT), as each patient reports unique challenges. In the fa…
R
ReachMD CME
1
Recent Advances and Emerging Approaches in the Treatment of Recurrent/Metastatic SCCHN: Matching the Patient to the Optimal Therapy
CME credits: 0.25 Valid until: 13-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/recent-advances-and-emerging-approaches-in-the-treatment-of-recurrentmetastatic-scchn-matching-the-patient-to-the-optimal-therapy/14495/ While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell c…
R
ReachMD CME
1
How Does RWE Expand Understanding of CDK4/6 Inhibitor Use in Special Populations With HR+/HER2- Metastatic Breast Cancer?
CME credits: 0.75 Valid until: 10-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/how-does-rwe-expand-understanding-of-cdk46-inhibitor-use-in-special-populations-with-hrher2-metastatic-breast-cancer/14784/ The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone re…
R
ReachMD CME
CME credits: 0.75 Valid until: 10-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-latest-real-world-evidence-with-cdk46-inhibitors-in-metastatic-hr-breast-cancer/14783/ The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive/human epi…
R
ReachMD CME
1
Interpretation and Application of RWE to Inform Shared Decision-Making in Metastatic HR+ Breast Cancer
CME credits: 0.75 Valid until: 10-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/interpretation-and-application-of-rwe-to-inform-shared-decision-making-in-metastatic-hr-breast-cancer/14785/ The introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has drastically changed the treatment landscape of hormone receptor-positive…
R
ReachMD CME
1
Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Panel Discussion
CME credits: 0.50 Valid until: 07-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/paradigm-shifts-in-car-t-cell-therapy-for-relapsedrefractory-large-b-cell-lymphoma/14589/ Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of large B-cell lymph…
R
ReachMD CME
1
Paradigm Shifts in CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: A Video Viewpoint
CME credits: 0.25 Valid until: 07-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/paradigm-shifts-in-car-t-cell-therapy-for-relapsedrefractory-large-b-cell-lymphoma-a-video-viewpoint/14588/ Since the first chimeric antigen receptor (CAR) T-cell therapy was approved by the US Food and Drug Administration (FDA) for the treatment of …
R
ReachMD CME
CME credits: 0.25 Valid until: 01-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/titrating-and-dosing-device-therapy-for-dre-best-practices-for-optimizing-patient-outcomes/14854/ Vagus nerve stimulation (VNS) therapy is an add-on neuromodulation treatment designed for adults and children diagnosed with drug-resistant epilepsy (DR…
R
ReachMD CME
CME credits: 0.50 Valid until: 31-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-gap-to-care-assessing-cad-and-improving-patient-outcomes-with-revascularization/14855/ Less than 20% of patients admitted to the hospital with new-onset heart failure are assessed for coronary artery disease (CAD) even though revasculariz…
CME credits: 0.50 Valid until: 31-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-2/13880/ This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD.…
R
ReachMD CME
CME credits: 0.50 Valid until: 30-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/predicting-type-1-diabetes-using-genetic-testing-or-islet-antibody-screening-are-we-there-yet/14286/ Autoantibody Screening to Identify Risk for Type 1 Diabetes T1D defines a continuum that begins during an asymptomatic prodrome before the disease ma…
CME credits: 0.50 Valid until: 24-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/case-management-strategies-for-patients-with-adpkd-part-1/13879/ This Expert Exchange webcast is designed to help improve clinicians’ ability to apply pharmacologic and non-pharmacologic strategies in the management of patients with ADPKD. =…
CME credits: 0.25 Valid until: 17-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/improving-meibomian-gland-dysfunction-with-device-management/14810/ How can more advanced measures improve meibomian gland function to relieve dry eye symptoms and improve refraction? Listen as Dr. Cynthia Matossian and Dr. Jillian Ziemanski discuss …
